The contingent of biotech and pharma companies condemning Russia’s invasion of Ukraine—and pledging to help keep the beleaguered nation’s healthcare system afloat—is growing.
Take Roche, for example. The Swiss pharma major on Wednesday said it would donate 150,000 packages of the antibiotic Rocephin to Ukraine. The drug is used to treat symptoms of many kinds of bacterial infections and holds a spot on the World Health Organization’s essential medicines list.
At the same time, the company said it “vehemently condemns the violent invasion of the country.”
Roche aims to get its Rocephin shipments to Ukraine “as soon as possible.” The company is working with external partners to figure out transport into the country “despite the current lack of humanitarian corridors into Ukraine,” Roche said in a release.
French drugmaker Sanofi also chimed in Thursday, sharing its sympathies with the Ukrainian people.
Sanofi says it’s donated 5 million euros ($5.5 million) to the Red Cross for Ukraine and neighboring countries, plus the U.N.’s refugee agency. The company is also hastening donations of essential medicines and vaccines to patients in Ukraine and Ukrainian refugees in nearby countries.
Meanwhile, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has started tracking the Ukrainian support efforts of drugmakers across the continent, including AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Pfizer, GlaxoSmithKline and more.
“Our first priority is to ensure that medicines reach the patients that need them in Ukraine, in the neighboring EU Member States, in Russia and in other countries where access to medicines may be negatively impacted,” EFPIA says on its website.
EFPIA’s member companies and associations are working to support Ukraine and help with the emerging refugee crisis in neighboring European countries. Companies are providing a mix of donations and financial support to non-governmental organizations.
Here are just a few of the actions those drugmakers have taken:
EFPIA has also recorded responses from Boehringer Ingelheim, Lundbeck and Merck. The federation says it’s updating its Ukraine response page regularly.
Across the industry, myriad companies have announced support efforts and individual decisions to halt operations within Russia, Reuters recently reported.
In biotech, leaders wrote in a recent letter that the industry’s “immediate and complete economic disengagement” from Russia is paramount. Chief executives at Nkarta, BioMarin, Rubius, atai Life Sciences, Blueprint Medicines, Ovid, Global Blood Therapeutics and dozens of others signed the letter.
The leaders pledged to cease investments in Russian companies and new investments within the country’s borders. They also promised to reject investments from Russian funds, halt collaboration or service agreements with Russian companies and halt trade with Russian companies, except for food and medicine.
In medtech, customized orthopedic implant maker Conformis on Wednesday said it would freeze all distribution to Russia and stop pursuing new business opportunities in the region.
Siemens Healthineers, meanwhile, told Fierce Medtech that it would comply with all export control requirements and sanctions, while continuing to support healthcare providers and patients in Russia, citing the universal right to medical care.
Johnson & Johnson, which told Fierce Medtech that the safety of affected employees and their families was its top priority, added that it’s “committed to ensuring that our essential medical products will reach the people who need them within the region.”
By Fraiser Kansteiner
Source: fiercepharma.com
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
